medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-790Research ArticleСтатьиВозможности индивидуального выбора гормонального контрацептиваPossibilities of individual choice of hormonal contraceptiveКузнецоваИ. В.KuznetsovaI. V.noemail@neicon.ruФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава РоссииРоссияFirst Moscow State Medical University n.a. I.M. SechenovRussian Federation201818072018322Современная гинекология1515Copyright © Кузнецова И.В., 20182018Кузнецова И.В.Kuznetsova I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/790

Комбинированная оральная контрацепция в настоящее время является не только средством предохранения от нежеланной беременности, но и методом профилактики и терапии целого ряда заболеваний. В России женщины не столь часто прибегают к использованию гормональных контрацептивов, как жительницы Европы, Северной и Южной Америки. Причинами недостаточного распространения гормональных противозачаточных средств в нашей стране являются недостаточная осведомленность о полезных свойствах контрацепции наряду с преувеличенным представлением о негативных последствиях приема гормонов, а также недостаток времени у медицинского персонала на адекватное консультирование и индивидуальный выбор препарата. Преодоление проблемы возможно при максимальном упрощении и оптимизации выбора гормонального контрацептивного средства для каждой конкретной женщины в зависимости от состояния ее здоровья, репродуктивного статуса и возраста.

Combined oral contraception is now not only a means of preventing unwanted pregnancy, but also a method of prevention and therapy of a number of diseases. In Russia, women do not often resort to the use of hormonal contraceptives, as residents of Europe, North and South America. The reasons for the insufficient distribution of hormonal contraceptives in our country are insufficient awareness of the useful properties of contraception, along with an exaggerated view of the negative consequences of taking hormones, as well as a lack of time for medical personnel to provide adequate counseling and individual drug selection. Overcoming the problem is possible with the maximum simplification and optimization of the choice of hormonal contraceptive for each specific woman, depending on her health status, reproductive status and age.

комбинированные оральные контрацептивылечебные эффекты гормональной контрацепциидиеногестдроспиренонгестоденципротерона ацетатcombined oral contraceptivestherapeutic effects of hormonal contraceptiondienogestdrospirenonegestodenecyproterone acetateReferencesSitruk-Ware R., Nath A., Mishell DR. Contraception technology: past, present and future. Contraception 2013; 87(3): 319-330.Sitruk-Ware R., Nath A., Mishell DR. Contraception technology: past, present and future. Contraception 2013; 87(3): 319-330.Veljkovic M., Veljkovic S. The risk of breast, cervical, endometrial and ovarian cancer in oral contraceptive users. Med Pregl. 2010; 63 (9-10): 657-661.Veljkovic M., Veljkovic S. The risk of breast, cervical, endometrial and ovarian cancer in oral contraceptive users. Med Pregl. 2010; 63 (9-10): 657-661.Dossus L., Allen N., Kaaks R., et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010; 127 (2): 442-451.Dossus L., Allen N., Kaaks R., et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010; 127 (2): 442-451.Vessey M., Yeates D., Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010; 82 (3): 221-229.Vessey M., Yeates D., Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010; 82 (3): 221-229.Schindler A.E. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013; 11 (1): 41-47.Schindler A.E. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013; 11 (1): 41-47.Weill A., Dalichampt M., Raguideau F., Ricordeau Ph., et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016; 353: i2002.Weill A., Dalichampt M., Raguideau F., Ricordeau Ph., et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ. 2016; 353: i2002.Mayeda E.R., Torgal A.H., Westhoff C.L. Weight and Body Composition Changes During Oral Contraceptive Use in Obese and Normal Weight Women. J Womens Health (Larchmt) 2014 Jan 1; 23 (1): 38-43.Mayeda E.R., Torgal A.H., Westhoff C.L. Weight and Body Composition Changes During Oral Contraceptive Use in Obese and Normal Weight Women. J Womens Health (Larchmt) 2014 Jan 1; 23 (1): 38-43.Blum R.W., Astone N.M., Decker M.R., et al. A conceptual framework for early adolescence: A platform for research. Int J Adolesc Med Health 2014; 26: 321e31.Blum R.W., Astone N.M., Decker M.R., et al. A conceptual framework for early adolescence: A platform for research. Int J Adolesc Med Health 2014; 26: 321e31.Anttila L., Bachmann G., Hernadi L., et al. Contraceptive efficacy of a combined oral contraceptive containing ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur Obstet Gynecol Reprod Biol. 2011; 155 (2): 180-182.Anttila L., Bachmann G., Hernadi L., et al. Contraceptive efficacy of a combined oral contraceptive containing ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. Eur Obstet Gynecol Reprod Biol. 2011; 155 (2): 180-182.Dinger J., Minh T.D., Buttmann N., et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117: 33-40.Dinger J., Minh T.D., Buttmann N., et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117: 33-40.Allen R.H., Cwiak C.A. Contraception for midlife women. Menopause 2016; 23 (1): 183-191.Allen R.H., Cwiak C.A. Contraception for midlife women. Menopause 2016; 23 (1): 183-191.Rothman K.J., Wise L.A., Sørensen H.T., Riis A.H., Mikkelsen E.M., Hatch E.E. Volitional Determinants and Age-related Decline in Fecundability: A General Population Prospective Cohort Study in Denmark. Fertil Steril. 2013; 99 (7): 1958-1964.Rothman K.J., Wise L.A., Sørensen H.T., Riis A.H., Mikkelsen E.M., Hatch E.E. Volitional Determinants and Age-related Decline in Fecundability: A General Population Prospective Cohort Study in Denmark. Fertil Steril. 2013; 99 (7): 1958-1964.Holinka C.F., Brincat M., Coelingh Bennink H.J.T. Preventive effect of oral estetrol in a menopausal hot flash model. Climacteric 2008; 11 (Suppl 1): 15-21.Holinka C.F., Brincat M., Coelingh Bennink H.J.T. Preventive effect of oral estetrol in a menopausal hot flash model. Climacteric 2008; 11 (Suppl 1): 15-21.Coelingh Bennink H.J.T., Heegaard A.-M., Visser M., Holinka C.F., Christiansen C. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric 2008; 11 (Suppl 1): 2-14.Coelingh Bennink H.J.T., Heegaard A.-M., Visser M., Holinka C.F., Christiansen C. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric 2008; 11 (Suppl 1): 2-14.Kannis J.A., Adams J., Borgström F., et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008; 42 (1): 4-15.Kannis J.A., Adams J., Borgström F., et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008; 42 (1): 4-15.Allali F., Mansouri L., Abourazzak F., et al. The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women. BMC Women's Health. 2009; 9: 31.Allali F., Mansouri L., Abourazzak F., et al. The effect of past use of oral contraceptive on bone mineral density, bone biochemical markers and muscle strength in healthy pre and post menopausal women. BMC Women's Health. 2009; 9: 31.Bonafede M.M., Miller J.D., Lukes A.S. et al. Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs. Clinin Econom Outcom Res 2014: 6423-429.Bonafede M.M., Miller J.D., Lukes A.S. et al. Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs. Clinin Econom Outcom Res 2014: 6423-429.Che Y., Liu X., Zhang B., Cheng L. Oral contraception following abortion: A systematic review and meta-analysis. Medicine (Baltimore) 2016; 95 (27): e3825.Che Y., Liu X., Zhang B., Cheng L. Oral contraception following abortion: A systematic review and meta-analysis. Medicine (Baltimore) 2016; 95 (27): e3825.Mueck A.O. Dinogest: an oral progestogen for the treatment of endometriosis. Expert Rev Obstet Gynecol. 2011; 6 (1): 5-15.Mueck A.O. Dinogest: an oral progestogen for the treatment of endometriosis. Expert Rev Obstet Gynecol. 2011; 6 (1): 5-15.Practice Bulletin. Noncontraceptive Uses of Hormonal Contraceptives. Obstet Gynecol 2010; 15 (1): 206-218.Practice Bulletin. Noncontraceptive Uses of Hormonal Contraceptives. Obstet Gynecol 2010; 15 (1): 206-218.Caruso S., Iraci M., Cianci S., et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest / 30 μg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016; 8: 923-931.Caruso S., Iraci M., Cianci S., et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest / 30 μg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016; 8: 923-931.ACOG Practice Bulletin No. 136: Management of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction. Obstet Gynecol. 2013; 122: 176-185.ACOG Practice Bulletin No. 136: Management of Abnormal Uterine Bleeding Associated With Ovulatory Dysfunction. Obstet Gynecol. 2013; 122: 176-185.ACOG. Management of acute abnormal uterine bleeding in non-pregnant women. Committee Opinion № 557. Obstet Gynecol. 2013; 121: 891-896.ACOG. Management of acute abnormal uterine bleeding in non-pregnant women. Committee Opinion № 557. Obstet Gynecol. 2013; 121: 891-896.Munro M.G., et al, for the FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Intern J Gynecol Obstet 2011; 113: 3-13. 33. SOGC. Abnormal Uterine Bleeding in Pre-Menopausal Women 2013; 35(5) (Suppl 1): 1-28.Munro M.G., et al, for the FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Intern J Gynecol Obstet 2011; 113: 3-13. 33. SOGC. Abnormal Uterine Bleeding in Pre-Menopausal Women 2013; 35(5) (Suppl 1): 1-28.Подзолкова Н.М., Кузнецова И.В. Применение марвелона в пролонгированном режиме в качестве противорецидивной терапии гиперпластических процессов эндометрия. Акушерство и гинекология 2007; 1: 53-57.Подзолкова Н.М., Кузнецова И.В. Применение марвелона в пролонгированном режиме в качестве противорецидивной терапии гиперпластических процессов эндометрия. Акушерство и гинекология 2007; 1: 53-57.Chandra V., Kim J.J., Benbrook D.M., Dwivedi A., Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016; 27 (1): e8.Chandra V., Kim J.J., Benbrook D.M., Dwivedi A., Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016; 27 (1): e8.Карахалис Л.Ю., Федорович О.К., Басина И.Б., Червонная И.Ю. Влияние патогенетически обоснованной терапии аденомиоза на его течение. Эффективная фармакотерапия. 2009; 5: 18-24.Карахалис Л.Ю., Федорович О.К., Басина И.Б., Червонная И.Ю. Влияние патогенетически обоснованной терапии аденомиоза на его течение. Эффективная фармакотерапия. 2009; 5: 18-24.Toxqui L., Perez-Granados A.M., Blanco-Rojo R., et al. A simple and feasible questionnaire to estimate menstrual blood loss: relationship with hematological and gynecological parameters in young women. BMC Women’s Health 2014; 14: 71.Toxqui L., Perez-Granados A.M., Blanco-Rojo R., et al. A simple and feasible questionnaire to estimate menstrual blood loss: relationship with hematological and gynecological parameters in young women. BMC Women’s Health 2014; 14: 71.Moorman P.G., Havrilesky L.J., Gierisch J.M., et al. Oral contraceptives and risk of ovarian cancer and breast cancer among highrisk women: a systematic review and meta-analysis. J Clin Oncol. 2013; 31: 4188-4198.Moorman P.G., Havrilesky L.J., Gierisch J.M., et al. Oral contraceptives and risk of ovarian cancer and breast cancer among highrisk women: a systematic review and meta-analysis. J Clin Oncol. 2013; 31: 4188-4198.Havrilesky L.J., Gierisch J.M., Moorman P.G., et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep) 2013; 212: 514.Havrilesky L.J., Gierisch J.M., Moorman P.G., et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep) 2013; 212: 514.Havrilesky L.J., Moorman P.G., Lowery W.J., et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013; 122: 139-47.Havrilesky L.J., Moorman P.G., Lowery W.J., et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013; 122: 139-47.Gierisch J.M., Coeytaux R.R., Urrutia R.P., et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013; 22 (11): 1931-1943.Gierisch J.M., Coeytaux R.R., Urrutia R.P., et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2013; 22 (11): 1931-1943.Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012; 7: CD 004425.Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012; 7: CD 004425.Рагимова З.Э., Каиль-Горячкина М.В. Междисциплинарные аспекты андроген-зави-симой дермопатии (обзор литературы). Consilium Medicum. Дерматология (прил.) 2016; 3: 56-62.Рагимова З.Э., Каиль-Горячкина М.В. Междисциплинарные аспекты андроген-зави-симой дермопатии (обзор литературы). Consilium Medicum. Дерматология (прил.) 2016; 3: 56-62.Sitruk-Ware R., Nath A. Characteristics and metabolic effects of estrogen and proges-tins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013; 27 (1): 13-24.Sitruk-Ware R., Nath A. Characteristics and metabolic effects of estrogen and proges-tins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013; 27 (1): 13-24.Bäckström T., Haage D., Löfgren M., Johansson I.M., et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience. 2011; 191: 46-54.Bäckström T., Haage D., Löfgren M., Johansson I.M., et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience. 2011; 191: 46-54.Brown J., O'Brien PMS, Marjoribanks J., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD 001396.Brown J., O'Brien PMS, Marjoribanks J., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD 001396.Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low-dose oral con -traceptive containing drospirenone: results of three multicentre trials. Clin Drug Invest 2009; 29 (2): 73-78.Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low-dose oral con -traceptive containing drospirenone: results of three multicentre trials. Clin Drug Invest 2009; 29 (2): 73-78.Аганезова Н.В., Линде В.А. Клинический опыт применения комбинированного монофазного орального контрацептива с дроспиреноном при синдроме предменструального напряжения. Пробл Репрод 2008; 1: 66-72.Аганезова Н.В., Линде В.А. Клинический опыт применения комбинированного монофазного орального контрацептива с дроспиреноном при синдроме предменструального напряжения. Пробл Репрод 2008; 1: 66-72.Rapkin A.J. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (suppl 9): 729-741.Rapkin A.J. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med 2008; 53 (suppl 9): 729-741.Breech L.L., Braverman P.K. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. Int J Womens Health. 2009; 1: 85-95.Breech L.L., Braverman P.K. Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder. Int J Womens Health. 2009; 1: 85-95.Геворкян М.А., Манухина Е.И., Смирнова С.О., Кузнецова Е.М. Профилактика формирования функциональных кист (клиническая лекция). Эффективная фармакотерапия, 2015.Геворкян М.А., Манухина Е.И., Смирнова С.О., Кузнецова Е.М. Профилактика формирования функциональных кист (клиническая лекция). Эффективная фармакотерапия, 2015.Moreau C., Cleland K, Trussel J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007; 76 (4): 267-272.Moreau C., Cleland K, Trussel J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007; 76 (4): 267-272.

The authors declare that there are no conflicts of interest present.